Further Encouraging COVID Results at Doherty
Released
Released
Announcement PDF
ASX Announcement
Encouraging Results from Anti-viral Screening Program at
The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2
Highlights:
•
RECCE® 327, a synthetic anti-infective 99.9% efficacious in confirmatory in-vitro
screening assay against SARS-CoV-2 virus
•
SARS-CoV-2 virus no-longer detectable by virus titration at 4,000ppm – minimal
toxicity to Vero cells
•
No toxicity identifiable at 1,333ppm or less
•
U.S. in-vivo studies in parallel expanded to include new UK & South African COVID
strains
Sydney Australia, 12 February 2021: Recce Pharmaceuticals Ltd (ASX: RCE) (Company),
the Company developing New Classes of Synthetic Anti-Infectives, today announced results
of RECCE® 327 (R327) demonstrating encouraging virucidal activity against the SARS-CoV2 virus with a positive safety profile.
The finding is based on independent tests conducted by the CSIRO/ Doherty Institute as part
of its SARS-CoV-2 Anti-viral Screening Program.
RECCE® 327 RT-PCR and Cell viability data
R327 showed a reduction in SARS-CoV-2 viral genome numbers at 4,000ppm and virus
was no longer detectable by viral titration; the RT-PCR detected the 3-log drop in viral
genome copies (99.9% reduction). PCR is a highly sensitive technique for viral detection and
quantitation – the first choice in COVID swab testing in humans and animals1. Antiviral testing
was conducted in triplicate with a very small variance bar above the 4,000ppm data point.
Minimal toxicity was observed at 4,000ppm of R327; there was no cytotoxicity at or below
1,333ppm.
Further testing will be required at higher dose levels to establish the IC 50 and cytotoxicity
which will then allow the Company to decide whether to pursue R327 as an anti SARS-CoV2
inhibitor candidate. Statistical signficance was not relevent in this study. All intellectual
property rights are retained by the Company with data to be reported as becomes available.
In parallel to the testing at CSIRO/Doherty Institute in Australia, a leading contract research
organisation in the United States is expanding its in-vivo studies of RECCE compounds
against SARS-CoV-2 in ferrets to include emerging UK and South African variant strains of
the virus. These studies continue to progress well with results on-track within the present
quarter.
Whilst Recce is delighted by the results, further testing must be completed before R327 is
confirmed as being active against the SARS-CoV-2 virus.
Non-Executive Chairman Dr. John Prendergast said, “We continue to be encouraged by the
results from the antiviral SARS-CoV-2 screening program as it reinforces our belief in the
potential of R327 against COVID-19 including emerging variant strains. We would like to
thank the Doherty Institute for performing the experiments and look forward to coming studies”
This announcement has been approved for release by Recce Pharmaceuticals Board.
1 https://pubmed.ncbi.nlm.nih.gov/21819328/
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New
Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic
resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics
RECCE® 327, RECCE® 435, and RECCE® 529 for viral infections with unique mechanisms of action
against hyper-mutation on bacteria and viruses, respectively.
Patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and
sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new
antibiotic compound, RECCE® 435, has been formulated for oral use.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the
Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10
years of market exclusivity post approval.
Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s
anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting
synergistic, unmet medical needs.
Share your feedback
Discover